Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-beta levels.

[1]  C. Byrne,et al.  Transforming growth factor beta is sequestered into an inactive pool by lipoproteins. , 1997, Journal of lipid research.

[2]  P. Ridker,et al.  Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. , 1997, Circulation.

[3]  D. Grainger,et al.  Tamoxifen: Teaching an old drug new tricks? , 1996, Nature Medicine.

[4]  D. Grainger,et al.  A PIVOTAL ROLE FOR TGF‐β* IN ATHEROGENESIS? , 1995 .

[5]  D. Grainger,et al.  Tamoxifen elevates transforming growth factor–β and suppresses diet–induced formation of lipid lesions in mouse aorta , 1995, Nature Medicine.

[6]  P. Grant,et al.  Environmental and Genetic Factors in Relation to Elevated Circulating Levels of Plasminogen Activator Inhibitor-1 in Caucasian Patients with Non-Insulin-Dependent Diabetes Mellitus , 1995, Thrombosis and Haemostasis.

[7]  L. Wakefield,et al.  Release and activation of platelet latent TGF–β in blood clots during dissolution with plasmin , 1995, Nature Medicine.

[8]  K. Huber,et al.  Tissue-type plasminogen activator and Type-1 plasminogen activator inhibitor in patients with coronary artery disease — Relations to clinical variables and cardiovascular risk factors , 1995 .

[9]  A. Hamsten,et al.  Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Weissberg,et al.  Active and acid-activatable TGF-β in human sera, platelets and plasma , 1995 .

[11]  B. Sobel,et al.  Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. , 1995, Circulation.

[12]  J. Yudkin,et al.  Determinants of Plasminogen Activator Inhibitor 1 Activity in Treated NIDDM and Its Relation to a Polymorphism in the Plasminogen Activator Inhibitor 1 Gene , 1995, Diabetes.

[13]  A. Grace,et al.  The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis , 1995, Nature Medicine.

[14]  A. Kulkarni,et al.  Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. , 1995, The American journal of pathology.

[15]  R. Lawn,et al.  Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice , 1994, Nature.

[16]  D. D. Bono,et al.  Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. , 1994 .

[17]  P. Weissberg,et al.  Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor beta-like activity from serum. , 1993, Cardiovascular research.

[18]  S. Thompson,et al.  Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[19]  P. Weissberg,et al.  Proliferation of human smooth muscle cells promoted by lipoprotein(a). , 1993, Science.

[20]  A. Henney,et al.  The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. , 1993, The Journal of biological chemistry.

[21]  J. Gamble,et al.  Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. , 1993, Journal of immunology.

[22]  T. Urano,et al.  Impaired fibrinolytic activity induced by ingestion of butter: effect of increased plasma lipids on the fibrinolytic activity. , 1993, Thrombosis research.

[23]  A. Hamsten,et al.  HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[24]  J. K. Dunn,et al.  Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[25]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[26]  A. Hamsten,et al.  Lipoprotein lipase in plasma after an oral fat load: relation to free fatty acids. , 1992, Journal of lipid research.

[27]  N. Crowther,et al.  Sensitive Amplified Immunoenzymometric Assays (IEMA) for Human Insulin and Intact Proinsulin , 1992, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[28]  L. Mannucci,et al.  Hypertriglyceridemia and regulation of fibrinolytic activity. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[29]  A. Gotto,et al.  Influence of short term dietary cholesterol and fat on human plasma Lp[a] and LDL levels. , 1991, Journal of lipid research.

[30]  D. Rifkin,et al.  Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration , 1991, The Journal of cell biology.

[31]  A. Hofman,et al.  Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[32]  A. Henney,et al.  Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[33]  C. Packard,et al.  Postprandial lipemia, fenofibrate and coronary artery disease. , 1990, Atherosclerosis.

[34]  D. Rifkin,et al.  Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self- regulating system , 1990, The Journal of cell biology.

[35]  A. Hamsten,et al.  The Fibrinolytic Enzyme System and Its Role in the Etiology of Thromboembolic Disease , 1990, Seminars in thrombosis and hemostasis.

[36]  F. Welt,et al.  Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2- macroglobulin inactive complex , 1989, The Journal of cell biology.

[37]  D. Owens,et al.  Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. , 1989, The Biochemical journal.

[38]  L. Bernstein,et al.  Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. , 1987, Atherosclerosis.

[39]  A. Gotto,et al.  Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. B. Zilversmit,et al.  Comparison of Cholesteryl Ester Transfer from Chylomicrons and Other Plasma Lipoproteins to Aortic Intima Media of Cholesterol‐Fed Rabbits , 1982, Arteriosclerosis.

[41]  D. B. Zilversmit.  Atherogenesis: a postprandial phenomenon. , 1979, Circulation.

[42]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.